Prevalence of Differentiated High-Grade Thyroid Carcinoma Among Well-Differentiated Tumors: A Systematic Review and Meta-Analysis
Thyroid® · 2024-03 · 34 (3) · 314-323
DOI: 10.1089/thy.2023.0350 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Thyroid®, online erschienen am 19.12.2023. Verfasst von Anello M Poma und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Neoplasm Grading. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Background
The current edition of the World Health Organization (WHO) classification of endocrine tumors introduced grading for follicular cell-derived thyroid cancer. Tumors with necrosis and/or high mitotic count but not fulfilling the Turin criteria for poorly differentiated carcinoma will be reclassified as differentiated high-grade thyroid carcinoma (DHGTC). However, the impact of this reclassification has not been evaluated. In this study, we performed a systematic review and meta-analysis to estimate the prevalence of this new entry across thyroid tumor subtypes.
Methods
In this systematic review and meta-analysis, studies reporting data on necrosis and/or mitoses in well-differentiated thyroid carcinoma (WDTC) were used to estimate the prevalence of DHGTC. Heterogeneity and potential publication bias were also evaluated. Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed, and quality assessment was performed using a modification of the Newcastle–Ottawa scale. The study has been registered in the International Prospective Register of Systematic Reviews (PROSPERO, ID: CRD42022378716).
Results
In clinically unselected patients, the prevalence of DHGTC in WDTC was 0.072 [95% confidence interval, CI, = 0.045–0.113]. The proportion of high-grade tumors greatly varied across growth patterns and subtypes. Overall, the prevalence of DHGTC was higher in follicular thyroid carcinoma (FTC; 0.146 [CI = 0.101–0.205]) than in papillary thyroid carcinoma (PTC; 0.059 [CI = 0.036–0.097]). Diffuse sclerosing, follicular, and classic subtype PTC had the lowest rates of high-grade features (i.e., 0.018 [CI = 0.004–0.084]; 0.036 [CI = 0.010–0.124]; and 0.042 [CI = 0.027–0.066], respectively), while a greater proportion of solid trabecular and histologically aggressive PTC could be reclassified as DHGTC (i.e., 0.154 [CI = 0.067–0.314] and 0.168 [CI = 0.108–0.252], respectively). Similar proportions were obtained for minimally and widely invasive FTC (i.e., 0.136 [CI = 0.058–0.287] and 0.152 [CI = 0.086–0.254], respectively). Finally, in a cohort of patients with poor prognosis (i.e., fatal cases, metastatic and radioiodine resistant tumors, cases with biochemical recurrence), the proportion of DHGTC was 0.287 [CI = 0.155–0.469].
Conclusions
Following the current WHO indications, some tumors will be reclassified as DHGTC. The proportion of tumors with high-grade features is relevant in FTC, solid trabecular, and histologically aggressive PTC subtypes. A remarkable enrichment in DHGTC among patients with poor prognosis confirms the negative impact of high-grade features on outcome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy.
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Anatomic Pathology, Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
- Solid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
ORCID-Profile: Anello M Poma, Fulvio Basolo
Förderung
- NCI NIH HHS
Zitieren
APA
Poma, A. M., Macerola, E., Ghossein, R. A., Tallini, G., & Basolo, F. (2024). Prevalence of Differentiated High-Grade Thyroid Carcinoma Among Well-Differentiated Tumors: A Systematic Review and Meta-Analysis. Thyroid®, 34(3), 314-323. https://doi.org/10.1089/thy.2023.0350
Vancouver
Poma AM, Macerola E, Ghossein RA, Tallini G, Basolo F. Prevalence of Differentiated High-Grade Thyroid Carcinoma Among Well-Differentiated Tumors: A Systematic Review and Meta-Analysis. Thyroid®. 2024;34(3):314-323. doi:10.1089/thy.2023.0350
BibTeX
@article{Poma2024,
author = {Poma, Anello M and Macerola, Elisabetta and Ghossein, Ronald A and Tallini, Giovanni and Basolo, Fulvio},
title = {Prevalence of Differentiated High-Grade Thyroid Carcinoma Among Well-Differentiated Tumors: A Systematic Review and Meta-Analysis},
journal = {Thyroid®},
year = {2024},
volume = {34},
number = {3},
pages = {314--323},
doi = {10.1089/thy.2023.0350}
}
EUVIMED